NOVOB80 Stock Price and Chart — SET:NOVOB80 — TradingView

Compare with Novo Nordisk A/S Units Thailand Depository Receipt Repr 0.001 Sh

Key facts today

Novo Nordisk (NOVO_B) faces ongoing litigation with Eli Lilly over an injunction tied to competing obesity and diabetes treatments; traders note legal timing and impact on competitive drug launches.

Analyze the impact Analyze the impact

Key stats

Upcoming earnings

Details

Novo Nordisk A/S is a global healthcare company, which engages in the discovery, development, manufacturing and marketing of pharmaceutical products. It operates through the Diabetes and Obesity Care and Rare Disease segments. The Diabetes and Obesity Care segment includes diabetes, obesity, cardiovascular, and emerging therapy areas. The Rare Disease segment refers to rare blood disorders, rare endocrine disorders, and hormone replacement therapy. The company was founded by Harald Pedersen and Thorvald Pedersen in 1923 is headquartered in Bagsværd, Denmark.

Financials

Performance

Revenue to profit conversion

Debt level and coverage

Earnings

Next:—

Ideas

$NVO , Idea Weekly chart. A pharma giant at a crossroads. NVO lost over 70% from its 2024 peak. The GLP-1 narrative cracked, competition arrived, and the market repriced brutally. Now at $43, it sits just above two major demand zones. Two scenarios on the table: Scenario 1 (yellow) : Capitulation into the $

NVO: Bullish Pennant Breakout Unlocks $+70$ Macro Target ### **The Macro Picture** Following a strong rally into early **2026**, **Novo Nordisk A/S ( NYSE:NVO $)** entered a healthy, multi-month consolidation phase. During this time, the price formed a textbook **Bullish Pennant** pattern, systematically carving out a series of lower highs and higher lows

by TaxpayerTrades

Novo Nordisk (NVO) | 1D Technical Analysis Novo Nordisk is approaching a critical technical inflection point after spending months in a primary downtrend. The recent price action is forming a Falling Wedge directly beneath the long-term descending trendline—a pattern that often precedes a bullish reversal when confirmed by a breakout. Marke

by IbrahimTarek

Novo Nordisk (NOV)Novo Nordisk (NVO) reported strong first-quarter earnings on May 6, 2026, with sales jumping 32% to reach 96.8 billion Danish kroner (~$15.2 billion). Driven by soaring demand for its popular GLP-1 weight-loss and diabetes drugs like Wegovy and Ozempic, the company beat earnings estimates and rais

NVO: Bullish Pennant Signals Potential Return to $150 Novo Nordisk appears to be developing a compelling long-term reversal setup after a prolonged decline from its previous highs. Following a significant selloff, price has spent several months building a base between $38 and $50. The recent recovery has pushed NVO back above a key psychological level

by TaxpayerTrades

NVO: Weekly Falling Wedge Lines Up With Key FVG Novo Nordisk (NVO) is basing after an extreme drawdown — the stock ran from ~$40 to ~$150 through 2024, then gave nearly all of it back in a sharp decline back to the low $40s on GLP-1 competition and trial-data pressure. Price just printed an +11.30% weekly reversal candle, closing at 48.07, and t

by TaxpayerTrades

Downtrend Breakout Reversal.Novo Nordisk (NVO) currently represents a high-quality large-cap growth franchise in a transitional market phase, where fundamentals and technicals are beginning to realign after a significant sentiment-driven drawdown. The company remains structurally advantaged with dominant positioning in the GLP

by Zanokuhle_Capital

$NVO (Novo Nordisk): 1-day. CUP & HANDLE breakout!NYSE:NVO (Novo Nordisk): 1-day Six days later, and in my opinion it's still the best-looking chart among the large-cap names. The price has reclaimed the green 200 MA ($47.8), which should now act as the main support zone if a pullback develops. I still think we're in Elliott Wave 3, so I'd consi

by ColdBloodedCharter

We're now on the verge of breaking above the channel.NYSE:NVO is now back above $50. Bought the exact bottom and still fully long. We're now on the verge of breaking above the channel. I think the higher-probability scenario is that we've transitioned into a trading range (yellow). If that's the case, we're now around the middle of that range, mak

by Swing_Trader_Saan

NVO: Massive Weekly Bullish Pennant Nearing Macro Breakout 📊 Macro Overview & Structural Context Looking at the NVO weekly chart, price action is currently compressing inside a massive, long-term Bullish Pennant pattern that has been forming since mid-2024. Following a powerful multi-year impulse wave, this extended correction has allowed the stock to fully

by TaxpayerTrades

See all ideas

Technicals

Summarizing what the indicators are suggesting.

Oscillators

Neutral

SellBuy

Strong sellStrong buy

Strong sellSellNeutralBuyStrong buy

Oscillators

Neutral

SellBuy

Strong sellStrong buy

Strong sellSellNeutralBuyStrong buy

Summary

Neutral

SellBuy

Strong sellStrong buy

Strong sellSellNeutralBuyStrong buy

Summary

Neutral

SellBuy

Strong sellStrong buy

Strong sellSellNeutralBuyStrong buy

Summary

Neutral

SellBuy

Strong sellStrong buy

Strong sellSellNeutralBuyStrong buy

Moving Averages

Neutral

SellBuy

Strong sellStrong buy

Strong sellSellNeutralBuyStrong buy

Moving Averages

Neutral

SellBuy

Strong sellStrong buy

Strong sellSellNeutralBuyStrong buy

Seasonals

Displays a symbol's price movements over previous years to identify recurring trends.

Highest yielding bonds

Maturity dateNov 20, 2045

Coupon4.00% (Fixed)

Maturity dateFeb 20, 2038

Coupon3.63% (Fixed)

Maturity dateMay 27, 2037

Coupon3.63% (Fixed)

Maturity dateFeb 20, 2035

Coupon3.38% (Fixed)

Maturity dateMay 21, 2034

Coupon3.38% (Fixed)

Maturity dateMay 27, 2033

Coupon3.13% (Fixed)

Maturity dateFeb 20, 2032

Coupon3.00% (Fixed)

Maturity dateJan 21, 2031

Coupon3.25% (Fixed)

Maturity dateAug 27, 2030

Coupon2.88% (Fixed)

Maturity dateJan 21, 2029

Coupon3.13% (Fixed)

Maturity dateMar 31, 2030

Coupon1.38% (Fixed)

See all NOVOB80 bonds